MMP9 and triple-A syndrome: ,629 These findings are supported by clinical observations showing that treatment with the PPARγ agonist pioglitazone reduces inflammation in AAA patients, evidenced by decreased macrophage infiltration in the aortic wall and periaortic adipose tissue, along with reduced expression of TNF-α and MMP-9.630